5:53 PM
 | 
Jul 17, 2013
 |  BC Extra  |  Company News

Pfizer licenses TB compound to Sequella

Pfizer Inc. (NYSE:PFE) granted anti-infectives company Sequella Inc. (Rockville, Md.) exclusive, worldwide rights to develop and commercialize the pharma's sutezolid, which is in Phase II testing to treat tuberculosis (TB). Sequella said it plans to develop the...

Read the full 172 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >